Safety and clinical efficacy of IRE ablation combined with NK cells in the treatment of primary liver cancer

Abstract

Abstract: Objective To investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer.Methods Between January 2017 and August 2019,80 patients were enrolled and randomly allocated to either the IRE group (n=40) or the IRE-NK group (n=40). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed.Results Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (P<0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status.Conclusion Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to con?rm these conclusions.

Key words: Irreversible electroporation, Natural killer cells, Primary liver cancer, Clinical trial

ZHANG Wei-hua, QIN Yan-qing, SHEN Jin-jie. Safety and clinical efficacy of IRE ablation combined with NK cells in the treatment of primary liver cancer[J]. Chinese Hepatolgy, 2020, 25(12): 1272-1274.

References

[1] 吕桂帅,陈磊,王红阳. 我国肝癌研究的现状与前景. 生命科学, 2015, 27: 237-248.
[2] 魏矿荣,彭侠彪,梁智恒,等. 全球肝癌流行概况. 中国肿瘤, 2015, 24: 621-630.
[3] 龚杰,宋云,徐尔侃,等. 肝癌的临床治疗新进展. 肝胆胰外科杂志, 2016, 28: 522-525.
[4] 杨玉媚,杜端明,陈继冰,等. 不可逆电穿孔消融治疗前列腺癌5例. 介入放射学杂志, 2018, 27: 854-859.
[5] Lin M, Liang S, Wang X, et al. Shortterm clinical ef?cacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunol Lett, 2017, 186: 20-27.
[6] Appelbaum L, Ben-David E, Faroja M, et al. Irreversible electroporation ablation: creation of large-volume ablation zones in in vivo porcine liver with fourelectrode arrays. Radiology, 2014,270:416-424.
[7] 孙钢. 不可逆电穿孔技术消融肿瘤研究进展. 介入放射学杂志, 2015, 24: 277-281.
[8] 姚陈果,赵亚军,李成祥,等. 不可逆电穿孔微创消融肿瘤技术的研究进展. 高电压技术, 2014, 40: 3725-3737.
[9] 任海龙,邵东燕,李琦,等. NK细胞应用于肿瘤免疫治疗的研究进展. 现代免疫学, 2017, 37: 233-237.
[10] 魏海荣,田志刚. NK细胞活化/抑制受体在慢性乙肝病毒感染中的发生发展//中国免疫学会第五届全国代表大会暨学术会议论文摘要. 中国江苏镇江: 20061.
[11] 孙玉英,孔繁华,奚永志. MHC结构与功能的研究进展. 中国实验血液学杂志, 2000: 227-230.
[12] Bulvik BE, Rozenblum N, Gourevich S, et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology, 2016, 280: 413-424.
[13] 张伟洁,郑宏. IL-6介导免疫炎性反应作用及其与疾病关系的研究进展. 细胞与分子免疫学杂志, 2017, 33: 699-703.

[1]	XU Xin-bao,YIN Jie, JI Hao-ming, QIAN Li. Effects of S-TACE combined with apatinib on tumor vascular factors, liver function and prognosis in patients with advanced primary liver cancer [J]. Chinese Hepatolgy, 2020, 25(9): 933-936.
[2]	HU Su-ling, LI Hong-jiang. The value of contrast-enhanced ultrasound with SonoVue in the differential diagnosis of atypical focal hepatic lesions [J]. Chinese Hepatolgy, 2020, 25(8): 835-836.
[3]	ZHOU Yan-ke, WANG Jing-min, TIAN Jing, LI Qian. Comparison of ultrasonographic characteristics between haptic neuroendocrine neoplasm and hepatocellular carcinoma [J]. Chinese Hepatolgy, 2020, 25(7): 686-688.
[4]	WANG Xiao, ZHOU Xi-jian, GU Pei. Study on the influencing factors of HBV reactivation after precise radiotherapy for primary liver cancer [J]. Chinese Hepatolgy, 2020, 25(7): 702-704.
[5]	WANG Yu, XU Da-feng, ZHOU Kai-lun, WU Jin-cai, DING Yi-chao, GU Hai-qiang, XIE Ming-wei, LIN Ming-hua.. Dynamic changes of TLR4 and intestinal flora in the progression of primary liver cancer and its relationship with prognosis [J]. Chinese Hepatolgy, 2020, 25(3): 273-276.
[6]	WANG Xian, LIN Tao-fa, ZHAN Zhi-yu, WANG Shao-yang. Differential expression of T lymphocyte and NK G2D in patients with chronic HBV infection in different immune states [J]. Chinese Hepatolgy, 2020, 25(2): 131-134.
[7]	WANG Jia-huan, LI Zhen. Clinical efficacy comparison of percutaneous radiofrequency ablation and laparoscopic liver resection for the treatment of stage Ia primary liver cancer [J]. Chinese Hepatolgy, 2020, 25(2): 146-148.
[8]	YANG Yun-fei, XIE Yi, JIAO Cheng-wen. Effect of different concentrations of iodine contrast agent on the blood perfusion parameters of primary liver cancer measured by 64-row multidetector computed tomography [J]. Chinese Hepatolgy, 2020, 25(11): 1175-1177.
[9]	CHEN Han-bo, WANG Heng-wu, CHEN Fu-jun. The establishment of preoperative prediction model for the prognosis of patients with primary liver cancer and portal vein tumor thrombus [J]. Chinese Hepatolgy, 2020, 25(10): 1052-1054.
[10]	WU Jie, DONG Gang, LIU Ting-ting, SUN Lu-lu. Clinical study of cold cycle microwave ablation combined with TACE in the treatment of primary liver cancer [J]. Chinese Hepatolgy, 2020, 25(10): 1058-1061.
[11]	SHI Guang-ying, ZHOU Fang, WANG Hong-xia, XIE Jing-dong. Tumor markers, IGF-1 and risk factors in patients with primary liver cancer [J]. Chinese Hepatolgy, 2020, 25(10): 1079-1082.
[12]	XIE Yun-bo, ZHANG Ji-yuan, YANG Tao, JIN Lei, WANG Song-shan, LIAN Fang, QU Rui, MA Xiao-fen, SHI Ming, DUAN Hai-feng, WANG Fu-sheng.. Phase Ⅰ study of HLA-halfmatched allogeneic natural killer cells therapy in patients with hepatocellular carcinoma [J]. Chinese Hepatolgy, 2017, 22(7): 581-584.
[13]	MAO An-rong, PAN Qi, ZHAO Yi-min, ZHANG Ning, ZHOU Jia-min, WANG Long-rong, WANG Yi-lin,LIN Zheng-hai,WANG Lu. Comparative study of 3 kinds of hepatic blood flow occlusion in hepatectomy for primary liver cancer complicated with liver cirrhosis [J]. Chinese Hepatolgy, 2017, 22(2): 116-118.
[14]	QIN Ya-nan, HONG Lei, SONG Zheng-xia, DING Qin. Clinical application of serum PIVKA-Ⅱ in diagnosis of primary liver cancer [J]. Chinese Hepatolgy, 2017, 22(12): 1103-1106.
[15]	HUANG Wen-qi, XU Jin-chao, MIN Feng, WU Wei-bing, FAN Rong-hua, ZHANG Li. Assessment value of indocyanine green clearance test for preoperative liver reserve function of patients with primary liver cancer [J]. Chinese Hepatolgy, 2017, 22(1): 6-.